ProCE Banner Activity

Strategies for Optimal HIV Treatment and Prevention: Considering a Switch to Long-Acting ART

Multimedia

In this case example, learn data and recommendations for considering a switch to long-acting CAB plus RPV, including current indications and contraindications, data for “direct to inject” without an oral lead-in, and considerations for dosing every 8 weeks vs every 4 weeks.

Released: July 22, 2022

Expiration: July 21, 2023

No longer available for credit.

Share

Faculty

Darcy Wooten

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant financial relationships to disclose.

Staff Disclosure

Staff

Jessica L. Adams, PharmD, AAHIVE

Scientific Director, Infectious Diseases
Clinical Care Options
New York, United States

Jessica Adams, PharmD, BCPS, has no relevant financial relationships to disclose.

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer Blanchette, PhD, has no relevant financial relationships to disclose.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant financial relationships to disclose.

Zachary Schwartz, MSc, ELS

Scientific Director

Petra Cravens, PhD, has no relevant financial relationships to disclose.